drugset
drugset / Trial / NCT02388152

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

NCT02388152 ↗

Phase 1 Terminated 50 enrolled H. Lundbeck A/S
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease.

Timeline

Start
2015-03
Primary completion
2019-07-04
Completion
2019-07-04

Outcome

Outcome not reported

Stopped: “New data: The study was terminated based on new efficacy data from another study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF20513 Unknown — —

Indications

Alzheimer disease